• 1
    Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 141824.
  • 2
    Bierer BE, Mattila PS, Standaert RF et al.. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990; 87: 92319235.
  • 3
    Sigal NH, Dumont FJ. Cyclosporin A. FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992; 10: 519560.
  • 4
    Vu MD, Qi S, Xu D et al.. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 18531856.
  • 5
    Qi S, Xu D, Peng J et al.. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 12751283.
  • 6
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376377.
  • 7
    McAlister VC, Mahalati K, Peltekian KM, Fraser A, Macdonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346350.
  • 8
    Oberbauer R, Kreis H, Johnson RW et al.. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study. Transplantation 2003; 76: 364370.
  • 9
    Legendre C, Mota A, Friend P et al.. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent-to-treat results at 3 years. American Transplant Congress, Washington , DC , May 30June 4, 2003.
  • 10
    Jimenez O, Campistol JM, Vidal E et al.. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation. Transplant Proc 2003; 35: 16861688.
  • 11
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit 2003; 25: 447451.
  • 12
    El-Sabrout R, Delaney V, Butt F et al.. Improved freedom from rejection after a loading dose of sirolimus. Transplantation 2003; 75: 8690.
  • 13
    Whelchel JD, Paczeq L, Bechstein WO, Russ G. A regimen of sirolimus and reduced-dose tacrolimus results in improved renal allograft function: combined analysis of the north American target, European and Australian sirolimus-tacrolimus trials. American Transplant Congress, Washington , DC , May 30June 4, 2003.
  • 14
    Lo A, Egidi MF, Gaber LW, Gaber AO. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. Transplant Proc 2003; 35: S105S108.
  • 15
    Lawen J, Keough-Ryan T, Clase C, Kiberd B. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. Transplant Proc 2001; 33: 32233225.
  • 16
    Kandaswamy R, Humar A, Khwaja K et al.. A prospective randomized study of cyclosporine (CsA)/Cellcept (MMF) vs. Tacrolimus (Tac)/sirolimus (Sir) with rapid discontinuation of prednisone (p.). American Transplant Congress, Washington , DC , May 30June 4, 2003.
  • 17
    Salazar A, McAlister VC, Kiberd BA, Bitter-Suermann H, Al-Kerithy MF, MacDonald AS. Sirolimus tacrolimus combination for combined kidney pancreas transplantation: Effect on renal function. Transpl Proc 2001; 33: 10381039.
  • 18
    Hricik DE, Anton HA, Knauss TC et al.. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189193.
  • 19
    Hricik DE, Knauss TC, Bodziak KA et al.. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76: 938942.
  • 20
    Van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 19341939.
  • 21
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 22
    Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.
  • 23
    Kreis H, Oberbauer R, Campistol JM et al.. Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 24
    Flechner SM, Goldfarb D, Modlin C et al.. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 25
    Morales JM, Wramner L, Kreis H et al.. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436442.
  • 26
    Gaber LW, Lo A, Egidi MF, Gaber AO. Renal protocol biopsy findings in patients receiving rapamycin based immunosuppression with or without low dose calcineurin inhibitor. American Transplant Congress, Washington , DC , May 30June 4, 2003.
  • 27
    Stallone G, Di Paolo S, Schena A et al.. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 9981003.
  • 28
    Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633638.
  • 29
    Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after ren al transplantation. Kidney Int 2002; 62: 8187.
  • 30
    Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551559.
  • 31
    Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen. incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375382.
  • 32
    Shapiro AM, Lakey JR, Ryan EA et al.. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230238.
  • 33
    Russ GR, Campbell S, Chadban S et al.. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc 2003; 35: S115S117.